Lead sponsor
AstraZeneca
20 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
20
Trials led
0
Ongoing
6,336
Total enrollment
621
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Early Phase 1
1
Phase 1
11
Phase 2
4
Phase 2/3
1
Phase 3
3
Trials by status
Completed
14
Terminated
6
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive ImpairmentAlzheimer's diseasePh 2Completed164
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With DonepezilAlzheimer's diseaseEarly Ph 1Completed155
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy SubjectsAge 60-80Ph 1Completed112
SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.Age 55-85Ph 1Completed77
Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy VolunteersHealthy volunteersPh 1Completed72
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's PatientsAlzheimer's diseasePh 1Completed47
To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's DiseaseAlzheimer's diseasePh 2Terminated40
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy AdultsAge 18-45Ph 1Completed27